Colorectal cancer is one of the most common malignancies diagnosed in Canada. 
Currently, adjuvant colorectal cancer treatment primarily includes 
chemotherapeutic regimens such as FOLFOX6 (5-fluorouracil, leucovorin, 
oxaliplatin) or CAPOX (capecitabine, oxaliplatin), as well as alternative 
regimens such as TOMOX (raltitrexed, oxaliplatin). However, the prevalence of 
drug shortages in today's society may make these preferred regimens 
inaccessible. The purpose of this case report is to highlight the tolerability 
of an alternative adjuvant regimen (pemetrexed plus oxaliplatin) that has 
undergone both phase I and II clinical trials for the treatment of colorectal 
cancer. The patient presented in this case report is a 57-year-old female 
diagnosed with Stage III colon cancer. This patient received seven cycles of 
pemetrexed plus oxaliplatin and experienced several adverse events, with the 
majority of them being mild in nature including fatigue and cold dysesthesia. 
However, the patient also experienced progressive neuropathy which required a 
dose reduction and subsequent discontinuation of oxaliplatin. Overall, 
pemetrexed and oxaliplatin's tolerability seems comparable to other regimens 
used to treat colorectal cancer and could potentially be an option to consider 
in the future for alternative treatment of colorectal cancer pending further 
trials.